Significance of reduction surgery in multidisciplinary treatment of advanced hepatocellular carcinoma with multiple intrahepatic lesions

被引:36
作者
Wakabayashi, H
Ushiyama, T
Ishimura, K
Izuishi, K
Karasawa, Y
Masaki, T
Watanabe, S
Kuriyama, S
Maeta, H
机构
[1] Takamatsu Natl Hosp, Dept Surg, Takamatsu, Kagawa 7610193, Japan
[2] Kagawa Med Univ, Dept Surg 1, Miki, Kagawa, Japan
[3] Kagawa Med Univ, Dept Internal Med 3, Miki, Kagawa, Japan
关键词
hepatocellular carcinoma; intrahepatic metastasis; reduction surgery; multidisciplinary treatment;
D O I
10.1002/jso.10203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives: By comparing the survival rates of patients treated with or without surgery, the significance of, and the indication for, reduction surgery in the multidisciplinary treatment of patients with HCC with multiple intrahepatic lesions were examined. Methods: In patients with HCC with multiple intrallepatic lesions, cumulative survival rates were determined and compared for 28 patients (group S) who underwent reductive hepatic resection and 43 (group N) who were treated nonsurgically by transcatheter arterial infusion chemotherapy (TAI), transcatheter arterial chemoembolization (TACE), or percutaneous transhepatic ethanol injection therapy. In group S, 20 patients had adjuvant therapy, consisting of ethanol injection therapy or microwave coagulonecrotic therapy for the remaining satellite lesions during hepatectomy, and all patients in this group underwent TAI or TACE postoperatively. The influence of surgery on patient survival was examined by multiple regression analysis using the Cox's hazard model; then, for each prognostic factor, survival rates were obtained and compared between the groups. Results: In group S, the 1-, 3-, and 5-year cumulative survival rates were 58.2%, 27.1 %, and 21.7%, whereas the corresponding values in group N were 34.3%, 4.7%, and 4.7%, the difference being statistically significant (P = 0.0239). In group S, the 1-, 3-, and 5-year cumulative survival rates for patients without intraoperative adjuvant therapy were 25%, 0%, and 0%, whereas those for patients with intraoperative adjuvant therapy were 72.7%, 41.3%, and 33.0% (P = 0.001). Multiple regression analysis showed that hepatic resection, the Child-Pugh score, and the size of the main tumor affected survival independently. Univariate analysis of differences in the cumulative survival rates between the groups as a function of prognostic factor showed that group S had statistically significant better survival rates than group N in those subgroups of patients who were <60 years old, with HBV infection, with a Child-Pugh score of 5 or 6, with a main tumor of <5-cm diameter, with <5 tumors, or without portal thrombi. Conclusions: When combined with intraoperative adjuvant therapy for remaining satellite tumors, reduction surgery provided survival benefit for patients with HCC with multiple intrahepatic lesions in those groups of patients selected by criteria determined in this study. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:98 / 103
页数:6
相关论文
共 25 条
[1]   Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan [J].
Arii, S ;
Yamaoka, Y ;
Futagawa, S ;
Inoue, K ;
Kobayashi, K ;
Kojiro, M ;
Makuuchi, M ;
Nakamura, Y ;
Okita, K ;
Yamada, R .
HEPATOLOGY, 2000, 32 (06) :1224-1229
[2]  
Asahara Toshimasa, 1998, Hiroshima Journal of Medical Sciences, V47, P115
[3]   Underlying liver disease, not tumor factors, predicts long-term survival alter resection of hepatocellular carcinoma [J].
Bilimoria, MM ;
Lauwers, GY ;
Doherty, DA ;
Nagorncy, DM ;
Belghiti, J ;
Do, KA ;
Regimbeau, JM ;
Ellis, LM ;
Curley, SA ;
Ikai, I ;
Yamaoka, Y ;
Vauthey, JN .
ARCHIVES OF SURGERY, 2001, 136 (05) :528-534
[4]   Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization [J].
Cheng, JCH ;
Chuang, VP ;
Cheng, SH ;
Lin, YM ;
Cheng, TI ;
Yang, PS ;
Jian, JJM ;
You, DL ;
Horng, CF ;
Huang, AT .
INTERNATIONAL JOURNAL OF CANCER, 2001, 96 (04) :243-252
[5]   CURRENT TREATMENT MODALITIES FOR HEPATOCELLULAR-CARCINOMA [J].
FARMER, DG ;
ROSOVE, MH ;
SHAKED, A ;
BUSUTTIL, RW .
ANNALS OF SURGERY, 1994, 219 (03) :236-247
[6]  
HAMAZOE R, 1995, CANCER, V75, P794, DOI 10.1002/1097-0142(19950201)75:3<794::AID-CNCR2820750308>3.0.CO
[7]  
2-5
[8]  
HERMANEK P, 1987, TNM CLASSIFICATION M, P59
[9]   Hepatocellular carcinoma [J].
Hussain, SA ;
Ferry, DR ;
El-Gazzaz, G ;
Mirza, DF ;
James, ND ;
McMaster, P ;
Kerr, DJ .
ANNALS OF ONCOLOGY, 2001, 12 (02) :161-172
[10]   INTRALESIONAL ETHANOL IN THE TREATMENT OF UNRESECTABLE LIVER-CANCER [J].
LIVRAGHI, T ;
LAZZARONI, S ;
MELONI, F ;
TORZILLI, G ;
VETTORI, C .
WORLD JOURNAL OF SURGERY, 1995, 19 (06) :801-806